Status:
TERMINATED
Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety of a short intravenous infusion of PT-523 to patients with solid tumors who have failed curative or survival prolonging therapy or for whom no such...
Detailed Description
The primary objectives of this study are 1) to evaluate the safety of a short intravenous infusion of PT-523 when administered on days 1, 8, and 15 of a 28-day cycle to patients with solid tumors who ...
Eligibility Criteria
Inclusion
- Presence of metastatic or inoperable malignancy, other than leukemia or a primary central nervous system (CNS) tumor, for which there is no known curative or survival prolonging palliative therapy, or failure of these therapies .
- Age greater than or equal to 18 years.
- Life expectancy greater than or equal to 2 months.
- ECOG performance status 0 - 2.
- Adequate organ function and bone marrow reserve.
- Use of appropriate contraceptive method.
- Sign patient informed consent.
Exclusion
- Active brain metastases.
- Presence of third-space fluid collections (pleural effusion, ascites).
- Major surgery within 3 weeks prior to dosing.
- Prior chemotherapy or radiation therapy within 3 weeks prior to dosing (6 weeks for nitrosoureas or mitomycin-C). Prior antifolate therapy is permitted, as long as it has not been administered within 3 weeks prior to dosing with PT-523.
- Prior bone marrow transplantation.
- Presence of uncontrolled serious medical or psychiatric illness.
- Patients requiring radiation therapy.
- There are no limitations on the extent or type of prior therapy received by the patient other than the time intervals indicated above, as long as the patient has demonstrated complete recovery from any adverse effects, and fulfills all relevant inclusion criteria.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00088023
Start Date
March 1 2004
End Date
December 1 2005
Last Update
March 31 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
3
Beth Isreal Deaconess Medical Center
Boston, Massachusetts, United States, 02215